Pfizer, Inc ( PFE ). shares are slightly higher on Thursday after the European Commission approved Pfizer’s DURVEQTIX.

Pfizer ( PFE ) announced Thursday that the European Commission approved a conditional marketing authorization for DURVEQTIX, a gene therapy for severe and moderately severe hemophilia B in adults whom meet certain criteria.

Hemophilia B is a rare genetic disorder that impairs blood clotting due to a deficiency in Factor IX, leading individuals with the condition to experience more frequent and prolonged bleeding.

“DURVEQTIX has shown the potential to offer long-term bleed protection in a one-time dose, reducing or eliminating bleeds for the appropriate patients with hemophilia B. These outcomes and their impact could become potentially transformative for hemophilia B care in the European Union,” said chief international commercial officer and executive vice president at Pfizer ( PFE ) Alexandre de Germay.

DURVEQTIX is already approved in the United States and Canada.

For the 2024 fiscal year second quarter, analyst estimates an EPS of 46 cents and revenue of $13.02 billion.

Related Link: GOP Strategist Asks Republicans To Challenge Joe Biden On Drug Pricing: ‘Go After It’

PFE Price Action: At the time of writing, Pfizer ( PFE ) shares are trading 1.55% higher $30.45 per data from Benzinga Pro.

Image: Photo via Shutterstock